Roughly 20,000 children under ten are diagnosed with psoriasis in the United States every year, yet the pediatric treatment landscape has long lagged well behind adult options. That gap narrowed meaningfully on June 26, when the FDA approved risankizumab for patients six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritisarthritis, a label that simultaneously covers both skin and joint disease in a single population.
The clinical case rests on the OptIMMize Phase 3 program, which enrolled children across two distinct cohorts: a randomized, efficacy assessor-blinded, active-controlled arm for adolescents aged 12 to under 18, and a single-arm open-label cohort for children aged 6 to under 12. At week 16 in Part 2 of the program, risankizumab produced clinically meaningful improvements in both sPGA and PASI responses, with durability maintained through continued treatment. The psoriatic arthritis indication in children rests on population pharmacokinetic modeling and simulation extrapolated from well-controlled adult PsA studies, a regulatory pathway that avoids running a standalone pediatric joint trial but that will draw scrutiny from clinicians who want direct joint-outcome data in children.
What makes the approval structurally notable is the new 55 mg pre-filled syringe, designed specifically for patients weighing less than 40 kg. Weight-based dosing in this range has historically been a practical barrier for biologics originally engineered around adult pharmacokinetics. The source identifies risankizumab as the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. IL-23 inhibition has been a dominant strategy in adult psoriatic disease since guselkumab’s approval in 2017, but that mechanism is only now reaching the lower end of the pediatric weight spectrum with an engineered dosage form to match.
The pediatric PsA label is the piece worth watching most closely. Approximately 14,000 children are affected by psoriatic arthritis in the U.S., a population where treatment decisions have long been complicated by limited labeled options and off-label extrapolation from adult data. Whether the pharmacokinetic modeling underpinning that approval holds up in real-world prescribing, particularly for joint outcomes in younger patients, will define how aggressively rheumatologists adopt this label versus waiting for direct efficacy data.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
